Application of bifidobacterium bifidum in preparation of composition for relieving acute kidney injury
By upregulating the expression of ZO-1, OCCLUDIN and MUC-2 genes through the Bifidobacterium bifidobacterium FL276.1 strain, the intestinal barrier and intestinal microbiota are solved, and the problems of intestinal barrier damage and flora disorders in AKI are provided. Safe and effective auxiliary treatment plans have enriched the probiotic library for improving kidney damage.
Patent Information
- Application Number
- CN202410982699.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Acute renal injury (AKI) lacks effective drug treatment, intestinal renal axis microbial disorders are related to renal inflammation, and the role of existing probiotics in AKI is not clear, and safe and non-toxic auxiliary treatment strategies are needed.
By upregulating the expression of ZO-1, OCCLUDIN and MUC-2 genes, the intestinal barrier is repaired, the intestinal flora is regulated, the intestinal flora is reduced, and the Scr and BUN levels are reduced, and the intestinal flora caused by AKI is corrected. Improperty, used in lyophilized bacteria powder, dairy products and other products.
It significantly improves the intestinal barrier function of AKI mice, inhibits inflammatory responses, corrects intestinal microbial disorders, enriches the probiotic library to improve kidney damage, and provides safe and effective auxiliary treatment plans.
Smart Images

Figure CN118902106A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of food microorganisms, in particular to application of Bifidobacterium bifidum in preparing a composition for alleviating acute kidney injury. Background Art
[0002] Acute kidney injury (AKI) is a syndrome in which renal function decreases sharply in a short period of time due to abnormal kidney structure or function. It has high morbidity and mortality and is also an important risk factor for chronic kidney disease and end-stage renal failure. Currently, there is no reliable drug treatment for AKI, and clinical treatment can only rely on expensive dialysis. Therefore, it is necessary to find effective ways to assist in the treatment of AKI.
[0003] The important role of the gut-kidney axis in the development of AKI is one of the hot research directions in recent years. A large number of studies have shown that intestinal microbial flora imbalance and intestinal barrier damage are associated with renal inflammation and acute renal injury. AKI is characterized by rapid decline in renal function and retention of nitrogenous waste. The former will increase the excretion load of enterogenic toxins, leading to the disorder of intestinal microbial flora. The latter will enhance the corrosiveness of the intestinal environment, erode the intestinal epithelial cells exposed therein, and cause impaired intestinal barrier function. Abnormal intestinal microbiota and damaged intestinal barrier will further affect the development of AKI, so restoring intestinal microbial homeostasis and repairing damaged intestinal barrier may be a prospective strategy to improve AKI. In this process, safe and non-toxic probiotics or their preparations have become a relatively potential object.
[0004] Studies have shown that certain probiotics can effectively slow the progression of AKI through the gut-kidney axis. It is reported that direct administration of Bifidobacterium preparations can supplement beneficial bacteria in the human intestine, restore the homeostasis of the intestinal microbiota, and repair the integrity of the intestinal barrier. In addition, Bifidobacterium can also inhibit intestinal inflammation, thereby improving intestinal immune function. However, the role and mechanism of Bifidobacterium bifidum in AKI are still unclear, and it is necessary to further explore the strains that can improve AKI, which will be of great significance in seeking auxiliary treatment strategies for AKI. Summary of the invention
[0005] The purpose of the present invention is to provide an application of Bifidobacterium bifidum in preparing a composition for alleviating acute kidney injury. Bifidobacterium bifidum FL276.1 can effectively improve the loss of intestinal barrier integrity in mice with acute kidney injury, and can also regulate the intestinal flora to alleviate acute kidney injury. It can be widely used in the preparation of probiotic products such as freeze-dried bacterial powder, dairy products and functional products thereof, enriching the probiotic library for developing products for improving kidney injury.
[0006] To achieve the above object, the present invention provides the use of Bifidobacterium bifidum in preparing a composition for alleviating acute kidney injury. The Bifidobacterium bifidum is Bifidobacterium bifidum FL276.1, and its 16S rDNA sequence is shown in SEQ ID NO.1.
[0007] Furthermore, Bifidobacterium bifidum FL276.1 can reduce Scr and BUN levels and repair pathological damage to kidney tissue.
[0008] Furthermore, the mechanism by which Bifidobacterium bifidum improves acute kidney injury is the upregulation of ZO-1, OCCLUDIN and MUC-2 gene expressions, and the restoration of intestinal mucosal barrier integrity.
[0009] Furthermore, the Bifidobacterium bifidum corrects the intestinal flora imbalance caused by AKI, while increasing the relative abundance of Enterorhabdus and reducing the relative abundance of Ruminococcus.
[0010] Furthermore, it is used to prepare freeze-dried bacterial powder, dairy products, and functional products.
[0011] Furthermore, the dosage of Bifidobacterium bifidum FL276.1 is 1×10 8 CFU / mL-1×10 9 CFU / mL.
[0012] The advantages and positive effects of the use of Bifidobacterium bifidum in the preparation of a composition for alleviating acute kidney injury according to the present invention are:
[0013] 1. The Bifidobacterium bifidum FL276.1 of the present invention significantly improves the impaired intestinal barrier function of mice with acute kidney injury by upregulating the gene expressions of ZO-1, OCCLUDIN and MUC-2 in the intestine and inhibits intestinal and systemic inflammatory responses.
[0014] 2. The Bifidobacterium bifidum FL276.1 of the present invention can correct the intestinal flora imbalance caused by AKI, while increasing the relative abundance of Enterorhabdus and reducing the relative abundance of Ruminococcus.
[0015] 3. The Bifidobacterium bifidum FL276.1 in the present invention can be used to prepare probiotic products such as freeze-dried bacterial powder, dairy products and functional products thereof, enriching the probiotic library for developing products to improve kidney damage.
[0016] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1These are the results of the effect of Bifidobacterium bifidum FL276.1 intervention on renal function in mice with acute renal injury in the examples of the present invention, wherein (a) is the result of Scr level, and (b) is the result of BUN level;
[0018] Figure 2 These are the results of the effect of Bifidobacterium bifidum FL276.1 intervention on renal tissue pathological damage in mice with acute kidney injury in the embodiments of the present invention, wherein (a) is the PAS staining analysis result of the CON group, (b) is the PAS staining analysis result of the AKI group, and (c) is the PAS staining analysis result of the FL276.1 group;
[0019] Figure 3 These are the results of the effect of Bifidobacterium bifidum FL276.1 intervention on the levels of inflammatory factors in mice with acute kidney injury in the examples of the present invention, wherein (a) is the result of IL-1β level in serum, (b) is the result of IL-6 level in serum, (c) is the result of IL-1β level in the intestine, and (d) is the result of IL-6 level in the intestine;
[0020] Figure 4 These are the results of the effect of Bifidobacterium bifidum FL276.1 intervention on the protein expression level of intestinal barrier function-related factors in the embodiment of the present invention, wherein (a) is the ZO-1 staining result, (b) is the OCCLUDIN staining result, and (c) is the MUC-2 staining result;
[0021] Figure 5 These are the results of the effect of Bifidobacterium bifidum FL276.1 intervention on the gene expression levels of intestinal barrier function-related factors in the embodiments of the present invention, wherein (a) is the result of ZO-1 expression level, (b) is the result of OCCLUDIN expression level, and (c) is the result of MUC-2 expression level;
[0022] Figure 6 Schematic diagram of the species differences between the FL276.1 group, the CON group and the AKI group at the genus level provided in the examples of the present invention. DETAILED DESCRIPTION
[0023] The technical solution of the present invention is further described below through the accompanying drawings and embodiments.
[0024] Unless otherwise defined, technical or scientific terms used in the present invention shall have the common meanings understood by one having ordinary skills in the field to which the present invention belongs.
[0025] Unless otherwise defined, the reagents involved in the embodiments of the present invention are purchased from commercial channels, and the methods not mentioned are conventional experimental methods and will not be described in detail here.
[0026] Example 1
[0027] Bifidobacterium bifidum FL276.1 alleviates acute kidney injury in mice.
[0028] Experimental Animals:
[0029] 7-week-old male C57BL / 6J mice were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. and received 12-h day-night cycle light, free access to drinking water and facilities during the breeding period. All mice were housed in the breeding laboratory of the Marine Biological Resources Development Center of Ocean University of China. The experiment was approved by the Experimental Animal Ethics Committee of the School of Food Science and Engineering of Ocean University of China, and the ethics review number is SPXY2023111411.
[0030] Test method:
[0031] After one week of adaptive feeding, the mice were weighed and randomly divided into two groups according to their body weight, namely, blank control group (CON) and disease modeling group (MOD). A diet containing 3% adenine induced acute kidney injury in mice in the MOD group. The CON group was fed the same food without the addition of adenine. After 3 days of treatment under this dietary pattern, there was no significant difference in the average body weight, so the MOD group mice were randomly divided into two groups, namely, disease control group (AKI) and FL276.1 intervention group (FL276.1). The CON group and AKI group were gavaged with 0.2 mL PBS / day / mouse, and the FL276.1 intervention group was gavaged with 0.2 mL 5×10 8 CFU / mL corresponds to bacterial suspension / day / mouse, and the mice were gavaged continuously for 21 days. After the experiment, the mice were anesthetized, blood was collected from the eye sockets, and the whole blood was centrifuged at 3000rpm to obtain serum. The mice were dissected and the colon and kidneys were removed. 1 cm of colon and longitudinal kidney tissue were fixed in 4% paraformaldehyde for histopathology, immunohistochemistry and fluorescence analysis. The remaining intestinal tissue and kidney tissue were temporarily stored in liquid nitrogen and transferred to -80℃ for use.
[0032] Mouse Scr and BUN levels were measured by a kit according to the instructions of the kit. Mouse kidney tissue pathological damage was analyzed by PAS staining.
[0033] The levels of inflammatory factors IL-1β and IL-6 in mouse serum and intestine were measured by ELISA. The specific operation was as follows: a section of colon tissue was weighed, ice-cold PBS containing protease inhibitors was added at a ratio of 1:9, and intestinal tissue homogenate was obtained by homogenization. The mixture was centrifuged at 3000 rpm for 10 min, and the supernatant was taken. According to the instructions of the reagent manufacturer, anti-mouse IL-1β ELISA and anti-mouse IL-6 ELISA kits were used to measure the levels of IL-1β and IL-6 in the intestine.
[0034] Test results:
[0035] Mouse Scr and BUN levels were measured by kits. Figure 1 It can be seen that compared with the AKI group, Bifidobacterium bifidum FL276.1 significantly reduced the increase in BUN and Scr levels caused by renal injury (p<0.001). Figure 2 As shown in the figure, PAS staining was performed on paraffin sections of kidney tissue to analyze its pathological damage, and it was found that intervention with Bifidobacterium bifidum FL276.1 reduced renal tissue pathological damage, such as tissue necrosis, tubular atrophy, and loss of brush edge.
[0036] ELISA was used to measure the levels of IL-1β and IL-6 in mouse serum and intestine. Figure 3 It can be seen that compared with the AKI group, Bifidobacterium bifidum FL276.1 effectively reduced the levels of IL-1β and IL-6 in the serum of AKI mice, and there was no difference with the CON group (p>0.05). In addition, Bifidobacterium bifidum FL276.1 can also significantly reduce the levels of IL-1β and IL-6 in colon tissue (p<0.05), and the trend of the results is consistent with that in serum.
[0037] Example 2
[0038] The mechanism by which Bifidobacterium bifidum FL276.1 alleviates acute kidney injury in mice.
[0039] Experimental animals and methods:
[0040] Based on the experimental animals of Example 1, the intestinal tissue fixed in paraformaldehyde was sent for immunohistochemical staining and immunofluorescence staining to analyze the expression of intestinal ZO-1, OCCLUDIN and MUC-2. The primary antibodies were Anti-ZO1 tightjunction protein Rabbit pAb, Anti-Occludin Rabbit pAb, and Anti-MUC2 Rabbit pAb. The sections were stained with DAPI, and images were captured using CaseViewer software. The mean fluorescence intensity was semi-quantitatively analyzed using Image J software.
[0041] qRT-PCR was used to analyze the gene expression of intestinal barrier-related factors ZO-1, OCCLUDIN, and MUC-2. Total RNA from the small intestine was extracted using Trizol reagent. cDNA was synthesized using a reverse transcription kit according to the manufacturer's instructions, and the gene levels of ZO-1, OCCLUDIN, and MUC-2 expressed in intestinal epithelial cells were detected using a fluorescent quantitative PCR instrument. -ΔΔCT The relative amount of mRNA transcripts was calculated by the PCR method and normalized by β-actin. The primers used are listed in Table 1.
[0042] Table 1 Primers used for qRT-PCR
[0043]
[0044] Test results:
[0045] Immunohistochemistry and immunofluorescence staining were used to analyze the expression of key factors related to intestinal barrier integrity, such as ZO-1, OCCLUDIN, and MUC-2. Figure 4 The staining results showed that Bifidobacterium bifidum FL276.1 could significantly reverse the decrease in ZO-1, OCCLUDIN and MUC-2 protein levels in the intestine of AKI mice (p<0.05). qRT-PCR results further confirmed that Bifidobacterium bifidum FL276.1 could effectively increase the expression of ZO-1, OCCLUDIN and MUC-2 genes in the intestine of AKI mice. Moreover, after Bifidobacterium bifidum FL276.1 intervention, the expression levels of ZO-1, OCCLUDIN and MUC-2 genes in the intestine were not significantly different from those in the CON group (p>0.05)( Figure 5 shown).
[0046] Example 3
[0047] Regulatory effects of Bifidobacterium bifidum FL276.1 on intestinal flora.
[0048] Experimental animals and methods:
[0049] Based on the experimental animals of Example 1, fecal samples were collected at the end of the experiment, immediately placed in liquid nitrogen and then transferred to -80° C. Changes in intestinal flora were analyzed by 16S rRNA microbiota gene sequencing.
[0050] 16S rRNA gene sequencing analysis of fecal samples revealed that Bifidobacterium bifidum FL276.1 increased the relative abundance of Enterorhabdus while decreasing the relative abundance of Ruminococcus ( Figure 6 Moreover, Bifidobacterium bifidumFL276.1 can correct the intestinal flora imbalance caused by AKI.
[0051] Example 4
[0052] Development of Bifidobacterium bifidum FL276.1 formulation.
[0053] The bacterial membrane concentrate of Bifidobacterium bifidum FL276.1 is centrifuged at 9000-12000rpm by a tubular centrifuge or a special fully automatic sterile butterfly centrifuge to obtain a bacterial sludge with a water content; the bacterial sludge is fully mixed with a special freeze-drying protective agent in a ratio of 1:1-2 to obtain a mixture, and the mixture is placed in a freezing plate of a -70°C freezer for rapid pre-freezing to 30-45°C and maintained for 30 minutes; the temperature is raised to -28°C at a rate of 5°C / 30min, and the temperature is maintained until the vacuum degree reaches 0.05MPa to complete the main drying stage; the temperature is raised to 10°C and the temperature is maintained until the vacuum degree reaches 0.03MPa to complete the analytical drying stage; the mixture is taken out and crushed with a granulator, and then packaged in a sterile aluminum foil box and stored in an environment of -20°C, thereby completing the preparation of plant lactobacillus freeze-dried powder.
[0054] The Bifidobacterium bifidum FL276.1 of the present invention can be used to prepare freeze-dried bacterial powder, probiotic fermentation agent, etc., and the functional strain can be added to functional dairy products such as milk powder and functional beverages, etc. However, the dairy products of the present invention are not limited thereto, and also include other forms of dairy products.
[0055] Therefore, the present invention adopts the above-mentioned Bifidobacterium bifidum in the preparation of a composition for alleviating acute kidney injury. Bifidobacterium bifidum FL276.1 can effectively improve intestinal barrier damage, and can also regulate intestinal flora to alleviate acute kidney injury. It can be widely used in the preparation of probiotic products such as freeze-dried bacterial powder, dairy products and their functional products, enriching the probiotic library for developing products to improve kidney damage.
[0056] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that they can still modify or replace the technical solution of the present invention with equivalents, and these modifications or equivalent replacements cannot cause the modified technical solution to deviate from the spirit and scope of the technical solution of the present invention.
Claims
1. Use of Bifidobacterium bifidum in preparing a composition for alleviating acute kidney injury, characterized in that: The Bifidobacterium bifidum is Bifidobacterium bifidum FL276.1, and its 16S rDNA sequence is shown in SEQ ID NO.
1.
2. The use according to claim 1, characterized in that: The bifidobacterium can reduce the levels of Scr and BUN and repair pathological damage of kidney tissue.
3. The use according to claim 1, characterized in that: The mechanism by which Bifidobacterium bifidum improves acute kidney injury is the upregulation of ZO-1, OCCLUDIN and MUC-2 gene expressions and the repair of the intestinal mucosal barrier.
4. The use according to claim 1, characterized in that: The Bifidobacterium bifidum corrects the intestinal flora imbalance caused by AKI, while increasing the relative abundance of Enterorhabdus and reducing the relative abundance of Ruminococcus.
5. The use according to claim 1, characterized in that: Used in the preparation of freeze-dried bacterial powder, dairy products, and functional products.
6. The use according to claim 1, characterized in that: The dosage of Bifidobacterium bifidum FL276.1 was 1×10 8 CFU / mL-1×10 9 CFU / mL.
Citation Information
Patent Citations
Bifidobacterium bifidum M2017063 and application thereof in preparation of drugs for relieving symptoms of chronic renal diseases
CN107586736A
Application of Lactobacillus casei Zhang to improvement of acute renal injury and prevention of renal interstitial fibrosis
CN109674827A
Composition for improving, treating or preventing renal failure comprising bifidobacterium bifidum BGN4
CN117425411A
Composition for improvemnet, prevention or treatment of kidney injury with Bifidobacterium bifidum BGN4
KR102362828B1
